Answer
Idarucizumab is a humanised monoclonal antibody fragment that specifically binds dabigatran and its metabolites with very high affinity, forming a very stable complex and neutralising their anticoagulant effect.
Sources for this answer
- Praxbind 2.5 g/50 mL solution for injection/infusionBoehringer Ingelheim Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 12Document updated
Sources checked